International definition of iMCD-TAFRO: future perspectives

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Thrombocytopenia, Anasarca, Fever, Reticulin fibrosis, Renal insufficiency, and Organomegaly (TAFRO) syndrome, first described in 2010, presents heterogeneously.
• TAFRO syndrome can manifest alongside infections, rheumatologic disorders, malignancies, and idiopathic multicentric Castleman disease (iMCD).
• A subtype, iMCD-TAFRO, has been identified, yet diagnostic confusion persists between TAFRO syndrome and iMCD-TAFRO.

Purpose of the Study:

• To clarify the current understanding of TAFRO syndrome and iMCD-TAFRO.
• To discuss the future research directions for these conditions.
• To highlight the implications of the new validated international definition.

Main Methods:

• Literature review and synthesis of existing research.
• Analysis of diagnostic criteria and clinical presentations.
• Discussion of recent advancements and proposed classifications.

Main Results:

• TAFRO syndrome is a distinct entity that can overlap with iMCD.
• iMCD-TAFRO represents a specific subtype within the broader TAFRO syndrome spectrum.
• A new international definition aims to reduce diagnostic ambiguity.

Conclusions:

• Clearer differentiation between TAFRO syndrome and iMCD-TAFRO is crucial for accurate diagnosis and management.
• Further research is needed to fully elucidate the pathogenesis and optimal treatment strategies.
• The validated international definition provides a framework for future studies and clinical practice.